Choose a language and wait for the translated text.
Drug developer Atavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche potentially worth nearly $2 billion, including milestone payments, to develop oral
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion | PharmaVoice
